Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
Objectives: To evaluate maternal and perinatal outcomes of pregnant women affected by SARS-COV-2.
Methods: This was a multinational retrospective cohort study including women with laboratory-confirmed SARS-COV-2 from 73 centers from 22 different countries in Europe, United States, South America, Asia and Australia from February 1, 2020 to April 30, 2020. Confirmed SARS-COV-2 infection was defined as a positive result on real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens. The primary outcome was a composite measure of maternal mortality and morbidity including admission to intensive care unit (ICU), use of mechanical ventilation, or death.
Results: 388 singleton pregnancies tested positive to SARS-COV-2 at RT-PCR nasal and pharyngeal swab were included in the study. The primary outcome was observed in 47/388 women (12.1%). 43/388 women (11.1%) were admitted to ICU, 36/388 (9.3%) required mechanical ventilation, and 3/388 women deceased (0.8%). Of the 388 women included in the study, 122 (31.4%) were still pregnant at the time of the study. Among the other 266 women, 6 had spontaneous first-trimester abortion, 3 had elective termination of pregnancy, 6 had stillbirth, and 251 delivered a live-born infant. The rate of preterm birth less than 37 weeks of gestation was 26.3% (70/266). Of the 251 live-born infants, 69/251 (27.5%) were admitted to NICU, with 5 neonatal deaths (2.0%). The overall rate of perinatal death was 4.1% (11/266). Only one infant (1/251, 0.4%) born from a mother tested positive during the third trimester, was found positive to SARS-COV-2 at RT-PCR.
Conclusions: SARS-COV-2 in pregnant women is associated with 0.8% rate of maternal mortality, but 11.1% rate of admission to ICU. The risk of vertical transmission seems to be negligible. This article is protected by copyright. All rights reserved.
Maternal and Perinatal Outcomes of Pregnant Women with SARS-COV-2 infection
Gabriele Saccone;Cihat Sen;Daniele Di Mascio;Alberto Galindo;Amos Grünebaum;Jun Yoshimatsu;Milan Stanojevic;Asım Kurjak;Frank Chervenak;María José Rodríguez Suárez;Zita Maria Gambacorti-Passerini;María de Los Angeles Anaya Baz;Esther Vanessa Aguilar Galán;Yolanda Cuñarro López;Juan Antonio De León Luis;Ignacio Cueto Hernández;Ignacio Herraiz;Cecilia Villalain;Roberta Venturella;Giuseppe Rizzo;Ilenia Mappa;Giovanni Gerosolima;Lars Hellmeyer;Josefine Königbauer;Giada Ameli;Tiziana Frusca;Nicola Volpe;Giovanni Battista Luca Schera;Stefania Fieni;Eutalia Esposito;Giuliana Simonazzi;Gaetana Di Donna;Aly Youssef;Anna Nunzia Della Gatta;Mariano Catello Di Donna;Vito Chiantera;Natalina Buono;Giulio Sozzi;Pantaleo Greco;Danila Morano;Beatrice Bianchi;Maria Giulia Lombana Marino;Federica Laraud;Arianna Ramone;Angelo Cagnacci;Fabio Barra;Claudio Gustavino;Simone Ferrero;Fabio Ghezzi;Antonella Cromi;Antonio Simone Laganà;Valentina Laurita Longo;Francesca Stollagli;Angelo Sirico;Antonio Lanzone;Lorenza Driul;Fabiana Cecchini;Serena Xodo;Brian Rodriguez;Felipe Mercado-Olivares;Deena Elkafrawi;Giovanni Sisti;Rosanna Esposito;Antonio Coviello;Marco Cerbone;Maddalena Morlando;Antonio Schiattarella;Nicola Colacurci;Pasquale De Franciscis;Ilaria Cataneo;Marinella Lenzi;Fabrizio Sandri;Riccardo Buscemi;Giorgia Gattei;Francesca Della Sala;Eleonora Valori;Maria Cristina Rovellotti;Elisa Done;Gilles Faron;Leonardo Gucciardo;Valentina Esposito;Flaminia Vena;Antonella Giancotti;Roberto Brunelli;Ludovico Muzii;Luigi Nappi;Felice Sorrentino;Marco Liberati;Danilo Buca;Martina Leombroni;Francesca Di Sebastiano;Massimo Franchi;Quintino Cesare Ianniciello;Simone Garzon;Giuliano Petriglia;Leonardo Borrello;Albaro Josè Nieto-Calvache;Juan Manuel Burgos-Luna;Caroline Kadji;Andrew Carlin;Elisa Bevilacqua;Marina Moucho;Pedro Viana;Rita Figueiredo;José Morales Roselló;Gabriela Loscalzo;Alicia Martinez-Varea;Vincente Diago;Jesús S Jimenez Lopez;Alicia Yeliz Aykanat;Stefano Cosma;Andrea Carosso;Chiara Benedetto;Amanda Bermejo;Otto Henrique May Feuerschuette;Ozlem Uyaniklar;Sakine Rahimli Ocakouglu;Zeliha Atak;Reyhan Gündüz;Esra Tustas Haberal;Bernd Froessler;Anupam Parange;Peter Palm;Igor Samardjiski;Chiara Taccaliti;Erhan Okuyan;George Daskalakis;Renato Augusto Moreira de Sa;Alejandro Pittaro;Maria Luisa Gonzalez-Duran;Ana Concheiro Guisan;Şerife Özlem Genç;Blanka Zlatohlávková;Anna Luengo Piqueras;Dolores Esteban Oliva;Aylin Pelin Cil;Olus Api;Panos Antsaklis;Liana Ples;Ioannis Kyvernitakis;Holger Maul;Marcel Malan;Albert Lila;Roberta Granese;Alfredo Ercoli;Giuseppe Zoccali;Andrea Villasco;Nicoletta Biglia;Ciuhodaru Madalina;Elena Costa;Caroline Daelemans;Axelle Pintiaux;Elif Gül Yapar Eyi;Elisa Cueto;Eran Hadar;Sarah Dollinger;Noa A Brzezinski-Sinai;Erasmo Huertas;Pedro Arango;Amadeo Sanchez;Javier Alfonso Schvartzman;Liviu Cojocaru;Sifa Turan;Ozhan Turan;Maria Carmela Di Dedda;Rebeca Garrote Molpeceres;Snezana Zdjelar;Tanja Premru-Srsen;Lilijana Kornhauser-Cerar;Mirjam Druškovič;Valentina De Robertis;Vedran Stefanovic;Irmeli Nupponen;Kaisa Nelskylä;Zulfiya Khodjaeva;Ksenia A Gorina;Gennady T Sukhikh;Giuseppe Maria Maruotti;Silvia Visentin;Erich Cosmi;Jacopo Ferrari;Alessandra Gatti;Daniela Luvero;Roberto Angioli;Ludovica Puri;Marco Palumbo;Giusella D'Urso;Francesco Colaleo;Agnese Maria Chiara Rapisarda;Ilma Floriana Carbone;Lamberto Manzoli;Maria Elena Flacco;Giovanni Nazzaro;Mariavittoria Locci;Maurizio Guida;Attilio Di Spiezio Sardo;Pierluigi Benedetti Panici;Asma Khalil;Vincenzo Berghella;Giuseppe Bifulco;Giovanni Scambia;Fulvio Zullo;Francesco D'Antonio
2020-01-01
Abstract
Objectives: To evaluate maternal and perinatal outcomes of pregnant women affected by SARS-COV-2.
Methods: This was a multinational retrospective cohort study including women with laboratory-confirmed SARS-COV-2 from 73 centers from 22 different countries in Europe, United States, South America, Asia and Australia from February 1, 2020 to April 30, 2020. Confirmed SARS-COV-2 infection was defined as a positive result on real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens. The primary outcome was a composite measure of maternal mortality and morbidity including admission to intensive care unit (ICU), use of mechanical ventilation, or death.
Results: 388 singleton pregnancies tested positive to SARS-COV-2 at RT-PCR nasal and pharyngeal swab were included in the study. The primary outcome was observed in 47/388 women (12.1%). 43/388 women (11.1%) were admitted to ICU, 36/388 (9.3%) required mechanical ventilation, and 3/388 women deceased (0.8%). Of the 388 women included in the study, 122 (31.4%) were still pregnant at the time of the study. Among the other 266 women, 6 had spontaneous first-trimester abortion, 3 had elective termination of pregnancy, 6 had stillbirth, and 251 delivered a live-born infant. The rate of preterm birth less than 37 weeks of gestation was 26.3% (70/266). Of the 251 live-born infants, 69/251 (27.5%) were admitted to NICU, with 5 neonatal deaths (2.0%). The overall rate of perinatal death was 4.1% (11/266). Only one infant (1/251, 0.4%) born from a mother tested positive during the third trimester, was found positive to SARS-COV-2 at RT-PCR.
Conclusions: SARS-COV-2 in pregnant women is associated with 0.8% rate of maternal mortality, but 11.1% rate of admission to ICU. The risk of vertical transmission seems to be negligible. This article is protected by copyright. All rights reserved.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3176336
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Citazioni
107
151
118
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.